PFIZER, INC.

(PFE)
  Report
Real-time Estimate Cboe BZX  -  08:38 2022-08-11 am EDT
48.48 USD   -2.95%
01:56aAdvent to sell Bioduro stake, eyes valuation over $1 billion - sources
RE
08/10PFIZER INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
AQ
08/10Acurx Pharmaceuticals Surges 29% In August, Here's Why The ACXP Bulls Expect Much More To Come ($ACXP)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

PFIZER, INC. : Ex-dividend day for

07/28/2022 EDT

A dividend is removed today from Pfizer, Inc.'s share.



© Factset 2022
All news about PFIZER, INC.
01:56aAdvent to sell Bioduro stake, eyes valuation over $1 billion - sources
RE
08/10PFIZER INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF ..
AQ
08/10Acurx Pharmaceuticals Surges 29% In August, Here's Why The ACXP Bulls Expect Much More ..
AQ
08/10UNIVERSITY OF BRISTOL : Increase in non-COVID-19 respiratory infections predicted this win..
AQ
08/10ViiV Healthcare Announces Support for Community-Based Organizations With New Monkeypox ..
AQ
08/10Pfizer spending spree filters to Biopharma
AQ
08/10Pfizer Managing Director Tenders Resignation
MT
08/09Novavax tumbles 30% as waning COVID-19 vaccine demand hits outlook
RE
08/09Global Blood Therapeutics Downgraded by RBC to Sector Perform From Outperform, Price Ta..
MT
08/09MARKETSCREENER’S WORLD PRESS REVIEW : August 9, 2022
MS
More news
Analyst Recommendations on PFIZER, INC.
More recommendations
Financials (USD)
Sales 2022 102 B - -
Net income 2022 32 675 M - -
Net cash 2022 11 522 M - -
P/E ratio 2022 8,86x
Yield 2022 3,24%
Capitalization 280 B 280 B -
EV / Sales 2022 2,64x
EV / Sales 2023 3,35x
Nbr of Employees 79 000
Free-Float 58,9%
Chart PFIZER, INC.
Duration : Period :
Pfizer, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 49,95 $
Average target price 56,53 $
Spread / Average Target 13,2%
EPS Revisions
Managers and Directors
Albert Bourla Chairman, Chief Executive & Operating Officer
David M. Denton Chief Financial Officer & Executive Vice President
Mikael Dolsten Executive VP, President-Research & Development
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Aida Habtezion Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
PFIZER, INC.-15.70%280 264
JOHNSON & JOHNSON-0.23%448 722
ELI LILLY AND COMPANY9.70%289 433
ROCHE HOLDING AG-16.02%278 152
ABBVIE INC.3.58%249 196
NOVO NORDISK A/S4.27%246 516